Literature DB >> 23981529

Synthesis and antiproliferative evaluation of novel benzoimidazole-contained oxazole-bridged analogs of combretastatin A-4.

Jie Zhou1, Jing Jin, Yi Zhang, Yuwen Yin, Xiaoguang Chen, Bailing Xu.   

Abstract

A series of novel oxazole-bridged analogs of combretastatin A-4 bearing a benzo[d]-imidazole as B ring were synthesized and evaluated for antiproliferative activities against five human cancer cell lines. Among all the synthesized compounds, the N-unsubstituted benzoimidazole analog 5 and the analogs 6b, 7a and 7b with a small hydrophobic group on nitrogen atom of benzoimidazole ring were identified as the most potent inhibitors of tumor cell growth with IC50 values at nanomolar levels (5, IC50=8.4 nM, HT29; 6b, 7a, 7b, IC50=9.6 nM, 3.8 nM, 3.0 nM, A549). In a murine H22 tumor xenograft model, compound 5 exhibited significant antitumor activity. The binding mode of compound 5 in the colchicine binding site of tubulin was probed.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Antiproliferative activity; Benzo[d]-imidazole; Combretastatin; Oxazole; Structure–activity relationship

Mesh:

Substances:

Year:  2013        PMID: 23981529     DOI: 10.1016/j.ejmech.2013.08.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  2 in total

1.  Effect of CPU-XT-008, a combretastatin A-4 analogue, on the proliferation, apoptosis and expression of vascular endothelial growth factor and basic fibroblast growth factor in human umbilical vein endothelial cells.

Authors:  Rui Xiong; Jing Sun; Kun Liu; Yungen Xu; Shuying He
Journal:  Oncol Lett       Date:  2015-11-05       Impact factor: 2.967

2.  Synthesis, anticancer activity and molecular docking studies on a series of heterocyclic trans-cyanocombretastatin analogues as antitubulin agents.

Authors:  Narsimha Reddy Penthala; Hongliang Zong; Amit Ketkar; Nikhil Reddy Madadi; Venumadav Janganati; Robert L Eoff; Monica L Guzman; Peter A Crooks
Journal:  Eur J Med Chem       Date:  2014-12-29       Impact factor: 6.514

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.